PTGES2 and RNASET2 identified as novel potential biomarkers and therapeutic targets for basal cell carcinoma: insights from proteome-wide mendelian randomization, colocalization, and MR-PheWAS analyses.

MLA

Han, Qiu-Ju, et al. “PTGES2 and RNASET2 Identified as Novel Potential Biomarkers and Therapeutic Targets for Basal Cell Carcinoma: Insights from Proteome-Wide Mendelian Randomization, Colocalization, and MR-PheWAS Analyses.” Frontiers in Pharmacology, vol. 15, July 2024, p. 1418560. EBSCOhost, https://doi.org/10.3389/fphar.2024.1418560.

APA

Han, Q.-J., Zhu, Y.-P., Sun, J., Ding, X.-Y., Wang, X., & Zhang, Q.-Z. (2024). PTGES2 and RNASET2 identified as novel potential biomarkers and therapeutic targets for basal cell carcinoma: insights from proteome-wide mendelian randomization, colocalization, and MR-PheWAS analyses. Frontiers in Pharmacology, 15, 1418560. https://doi.org/10.3389/fphar.2024.1418560

Chicago

Han, Qiu-Ju, Yi-Pan Zhu, Jing Sun, Xin-Yu Ding, Xiuyu Wang, and Qiang-Zhe Zhang. 2024. “PTGES2 and RNASET2 Identified as Novel Potential Biomarkers and Therapeutic Targets for Basal Cell Carcinoma: Insights from Proteome-Wide Mendelian Randomization, Colocalization, and MR-PheWAS Analyses.” Frontiers in Pharmacology 15 (July): 1418560. doi:10.3389/fphar.2024.1418560.